ELEDON PHARMACEUTICALS

Eledon to Present Data from Ongoing Phase 1b Trial Evaluating Tegoprubart in Kidney Transplantation at the World Congress of Nephrology 2023

23 3 2023 07:00:02 提供 Nasdaq GlobeNewswire

Eledon Pharmaceuticals to Present at SVB Securities Global Biopharma Conference

08 2 2023 15:05:00 提供 Nasdaq GlobeNewswire

Eledon Pharmaceuticals Provides Business and Pipeline Updates

09 1 2023 07:31:00 提供 Nasdaq GlobeNewswire

C-Path's Transplant Therapeutics Consortium Receives EMA Qualification Opinion for iBox Scoring System

21 12 2022 15:05:00 提供 Nasdaq GlobeNewswire

Eledon Pharmaceuticals Reports Third Quarter 2022 Operating and Financial Results

14 11 2022 15:01:00 提供 Nasdaq GlobeNewswire

Eledon Pharmaceuticals to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022

03 11 2022 15:05:01 提供 Nasdaq GlobeNewswire

Eledon Pharmaceuticals Announces Upcoming Presentations at ASN’s Kidney Week 2022 and NEALS

24 10 2022 15:05:00 提供 Nasdaq GlobeNewswire

Eledon Pharmaceuticals to Participate in Two Upcoming Conferences

03 10 2022 07:00:01 提供 Nasdaq GlobeNewswire

Eledon Pharmaceuticals to Present at Ladenburg Thalmann Healthcare Conference

22 9 2022 15:05:00 提供 Nasdaq GlobeNewswire

Eledon Pharmaceuticals Receives FDA Clearance of IND Application to Evaluate Tegoprubart in IgA Nephropathy

06 9 2022 15:01:00 提供 Nasdaq GlobeNewswire

Eledon Pharmaceuticals to Participate in Two Upcoming Investor Conferences

29 8 2022 07:00:00 提供 Nasdaq GlobeNewswire

Eledon Pharmaceuticals Reports Second Quarter 2022 Operating and Financial Results

11 8 2022 15:01:00 提供 Nasdaq GlobeNewswire

Eledon Pharmaceuticals to Report Second Quarter 2022 Financial Results on Thursday, August 11, 2022

04 8 2022 15:05:03 提供 Nasdaq GlobeNewswire

Eledon Pharmaceuticals Announces the First Patient Dosed in Phase 1b Trial Evaluating Tegoprubart in Kidney Transplantation

18 7 2022 07:00:01 提供 Nasdaq GlobeNewswire

Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

10 6 2022 15:05:00 提供 Nasdaq GlobeNewswire

Eledon Pharmaceuticals Announces Orphan Drug Designation Granted to Tegoprubart for the Prevention of Allograft Rejection in Pancreatic Islet Cell Transplantation

09 6 2022 07:00:01 提供 Nasdaq GlobeNewswire

Eledon Pharmaceuticals to Present at the Jefferies Healthcare Conference

02 6 2022 15:05:00 提供 Nasdaq GlobeNewswire

Eledon Announces Positive Topline Results from Phase 2a Trial of Tegoprubart Demonstrating Safety, Target Engagement, and Biomarker Response in Patients Living with Amyotrophic Lateral Sclerosis

31 5 2022 05:00:00 提供 Nasdaq GlobeNewswire

Eledon Pharmaceuticals Reports First Quarter 2022 Operating and Financial Results

12 5 2022 15:01:00 提供 Nasdaq GlobeNewswire

Eledon Pharmaceuticals Announces First Patient Dosed in Phase 2a Trial Evaluating Tegoprubart in IgA Nephropathy

09 5 2022 07:00:02 提供 Nasdaq GlobeNewswire